Compositions and methods for treating synucleinopathies
The present invention describes the use of a 5HT3-antagonist, in combination with a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, to reduce adverse effects and to facilitate the neuroprotective treatment of a patient suffering from a synucleinopathic disorder to enable a therapeutically effective 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine daily dose without the dose-limiting adverse effects caused by pramipexole when administered alone.
1. A method for treating a synucleinopathy in a patient, which comprises administering to said patient in need of said treatment an effective daily dose of a 5HT3-antagonist in combination with a therapeutically effective daily dose of a 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine.
2. The method of claim 1 , wherein said 5HT3-antagonist effective daily dose is from 1 mcg to 300 mg.
3. The method of claim 1 , wherein said 5HT3-antagonist is ondansetron or a pharmaceutically acceptable salt or solvate thereof.
4. The method of claim 1 , wherein said 5HT3-antagonist is dolasetron or a pharmaceutically acceptable salt or solvate thereof.
5. The method of claim 1 , wherein said 5HT3-antagonist is ondansetron hydrochloride dihydrate and said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine is pramipexole dihydrochloride monohydrate.
6. The method of claim 1 , wherein said 5HT3-antagonist is ondansetron hydrochloride dihydrate, said effective daily dose (in ondansetron) being from 4 mg to 32 mg and said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine is pramipexole dihydrochloride monohydrate, said daily therapeutically effective dose of said pramipexole dihydrochloride monohydrate being from 1.5 mg to 42 mg.
7. The method of claim 1 , wherein said 5-HT3-antagonist and said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine are each formulated in a pharmaceutical composition in dosage unit form comprising said 5-HT3-antagonist and, respectively, said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, each in admixture with a pharmaceutical carrier or vehicle.
8. The method of claim 1 , wherein said 5-HT3-antagonist and said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine are each formulated in a pharmaceutical composition in dosage unit form comprising said 5-HT3-antagonist in an amount per unit form of from 1 μg to 300 mg, and, respectively, said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine in an amount per unit of from 0.125 mg to 3000 mg; each in admixture with a pharmaceutical carrier or vehicle.
9. The method of claim 1 , wherein said 5-HT3-antagonist and said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine are each formulated in a pharmaceutical composition in dosage unit form comprising said 5-HT3-antagonist in an amount per unit form of from 1 μg to 300 mg, and, respectively, said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine is pramipexole dihydrochloride monohydrate in an amount per unit form of from more than 4.5 mg to 42 mg.
10. The method of claim 9 , wherein said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine is pramipexole dihydrochloride monohydrate in an amount per unit form of from more than 6 mg to 42 mg.
11. The method of claim 9 , wherein said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine is pramipexole dihydrochloride monohydrate in an amount per unit form of from 6.5 mg to 42 mg.
12. The method of claim 1 , wherein said 5-HT3-antagonist and said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine are co-formulated in a pharmaceutical composition in dosage unit form comprising said 5-HT3-antagonist, in an amount per unit form of from 1 μg to 300 mg, and said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine, in an amount per unit form of from 0.125 mg to 3000 mg, in admixture with a pharmaceutical carrier or vehicle.
13. The method of claim 1 , wherein said 5-HT3-antagonist and said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine are co-formulated in a pharmaceutical composition in dosage unit form comprising said 5-HT3-antagonist, in an amount per unit form of from 1 mcg to 300 mg, and said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine is selected from the group consisting of pramipexole and pharmaceutically acceptable salts and solvates thereof, in an amount per unit form equivalent to from 0.125 mg to 42 mg of pramipexole dihydrochloride monohydrate, in admixture with a pharmaceutical carrier or vehicle.
14. The method of claim 13 , wherein, in said composition, said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine is pramipexole dihydrochloride monohydrate in an amount per unit form of from more than 4.5 mg to 42 mg.
15. The method of claim 13 , wherein, in said composition, said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine is pramipexole dihydrochloride monohydrate in an amount per unit form of from more than 0.6 mg to 42 mg.
16. The method of claim 13 , wherein, in said composition, said 5HT3-antagonist is ondansetron hydrochloride dihydrate, in an amount per unit for equivalent to from 2 mg to 32 mg of ondansetron base and said 6-propylamino-4,5,6,7-tetrahydro-1,3-benzothiazole-2-amine is pramipexole dihydrochloride monohydrate, in an amount per unit form of from 0.125 mg to 42 mg.
17. The method of claim 1 , wherein said synucleinopathy is selected from the group consisting of Parkinson's disease, Lewy body dementia, mutations in the glucocerebrosidase gene, and multiple system atrophy.